Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making
January 6, 2010
By:George Koroneos, Online Content & News Editor
It's just a few days into the new year and already a potential megamerger has been announced: Novartis offered $39 billion for complete control of ocular drug manufacturer Alcon.
 |
November 4, 2009
By:Walter Armstrong, Senior Editor
A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much.
|
September 16, 2009
By:George Koroneos, Online Content & News Editor
Elan was forced to trim $100 million off its billion-dollar deal with J&J due to a 50/50 agreement with Biogen Idec involving co-ownership of MS drug Tysabri. Now J&J is out a major drug, Elan is out a good chunk of cash, and Biogen Idec is pondering its next move.
|
June 10, 2009
By:George Koroneos, Online Content & News Editor
GlaxoSmithKline is expanding its influenza vaccine efforts through a joint R&D alliance with Shenzhen Neptunus. The goal: to tap the world’s biggest market and attempt to deliver flu shots to more than a billion people.
|
June 3, 2009
By:George Koroneos, Online Content & News Editor
GlaxoSmithKline has entered into a collaboration deal with Concert to create drugs using deuterium—“heavy hydrogen”—that can be gathered from seawater and used to alter the way molecules perform in the body.
|
April 22, 2009
Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line.
|
April 22, 2009
By:George Koroneos, Online Content & News Editor
The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market.
|
April 1, 2009
From the depths of the Great Recession, Pharm Exec called in pros on all sides of the M&A business to help us deal.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
The New Health is the fast-morphing world of biopharma: emerging science, changing technology, rising costs, global regulations. The New Health needs an ally. More at www.quintiles.com/newhealth.
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA